Further, RA patients with serious infections before the initiation of TNF-α inhibitor therapy were not at increased risk of subsequent serious infection and the hospitalization rate was comparable between patients continuously treated with the same TNF-α inhibitor and patients who switched to another TNF-α inhibitor, or even to a different mode of action [54]. Here, TNF is linked to infection.